Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma
Ann Surg Oncol
.
2023 Sep;30(9):5329-5332.
doi: 10.1245/s10434-023-13736-5.
Epub 2023 Jun 19.
Authors
Cimarron E Sharon
1
,
Gabriella N Tortorello
2
,
Kevin Ma
3
,
Andrew J Sinnamon
4
,
Tara C Mitchell
5
,
Giorgos C Karakousis
3
,
John T Miura
3
Affiliations
1
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
[email protected]
.
2
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
3
Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
4
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
5
Division of Medical Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
PMID:
37332026
PMCID:
PMC11218604
DOI:
10.1245/s10434-023-13736-5
No abstract available
Publication types
Letter
MeSH terms
Adjuvants, Immunologic
Humans
Immunotherapy
Melanoma* / therapy
Melanoma, Cutaneous Malignant
Skin Neoplasms* / therapy
Substances
Adjuvants, Immunologic
Grants and funding
P50 CA261608/CA/NCI NIH HHS/United States
P50 CA 261608/NH/NIH HHS/United States